Font Size

Notice body

Researchers from the Auburn University Research Initiative in Cancer, or AURIC, and Nuovo Biologics LLC, of Davie, Florida, have announced a partnership to develop new therapies for cancer.

Initially targeting canine malignant melanoma, or skin cancer, a deadly tumor that affects many dogs, the team will be testing Nuovo’s innovative anti-cancer peptide drug MMX for its ability to treat these tumors.

The National Institutes for Health recently awarded a grant funded by the U.S. Food and Drug Administration to support a clinical trial of the new peptide treatment. According to Dr. Bruce Smith, director of AURIC and leader of the Auburn component of the research effort, the clinical trial will begin to recruit patients as early as June or July. For more information, visit this website.